Phone: 08 8128 4366
Bachelor of Science, University of Adelaide
Bachelor of Science (Hons), Flinders University
Doctor of Philosophy (Medicine), University of Adelaide
As the Research Manager for the Prostate Cancer Research Group I am responsible for administration for the group’s projects as well as managing activities of the Movember Revolutionary Team Award, which includes numerous researchers located in Australia, New Zealand, Europe and North America. My role encompasses facilitating communication between collaborators, liaison with internal and external stakeholders, preparation of research grants, manuscripts, reports and ethics submissions, staff appointments, promotions and budgeting and financial management.
17 journal articles and 1 book chapter published since 2001. Publications since 2010 include:
- Moore NL, Edwards DP and Weigel NL. Cyclin A2 and its Associated Kinase Activity are Required for Optimal Induction of Progesterone Receptor Target Genes in Breast Cancer Cells. J Steroid Biochem Mol Biol 144 Pt B:471-82, 2014.
- Moore NL*, McNamara KM*, Hickey TE, Sasano H and Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 21:T161-81, 2014. * equal first authors.
- Moore NL*, Centenera MM*, Butler LM, Hickey TE and Tilley WD. Androgen and the Androgen Receptor, in: Gelmann E, Sawyers C and Rauscher F III (Eds.), Molecular Oncology: Causes of Cancer and Targets for Treatment, Chapter 32:378-391, 2014. Cambridge University Press, New York. * equal first authors.
- Moore NL*, Ochnik AM*, Jankovic-Karasoulos T, Bianco-Miotto T, Ryan NL, Thomas MR, Birrell SN, Butler LM, Tilley WD and Hickey TE. The anti-androgenic actions of medroxyprogesterone acetate in epithelial cells within normal human breast tissues cultured ex vivo. Menopause 21:79-88, 2014. * equal first authors.
- Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE and Tilley WD. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr Relat Cancer 19: 599-613, 2012.
- Moore NL, Hickey TE, Butler LM and Tilley WD. Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Mol Cell Endocrinol 357: 60-70, 2011.
- Moore NL and Weigel NL. Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. International J Biochem Cell Biol 43: 1157-67, 2011.
- Tilley WD, Moore NL and Tarulli GA. Preventing breast cancer by harnessing the selective inhibitory power of a novel androgenic agent, enobosarm. National Breast Cancer Foundation Pilot Study Award, 2015-2016; $199,850.
- Tilley WD, Hickey TE, Moore NL and Carroll JS. Targeting the androgen receptor in triple negative breast cancer. Cancer Australia Priority-driven Collaborative Cancer Research Scheme, 2013-2015; $589,424.
- Moore NL. Medroxyprogesterone acetate action in the breast: implications for breast cancer risk in users of hormone replacement therapy. National Breast Cancer Foundation Novel Concept Award, 2012-2013; $199,915.
- Penniment MG, Giles E, McGee M, Casey P and Moore NL. A single-blinded randomised controlled trial to determine the effect of topical application of Calendula officialis based lotion on the prevalence of clinically significant radiation induced dermatitis in women undergoing radiotherapy for breast cancer. Royal Adelaide Hospital Clinical Project Grant, 2012; $34,500.